118 related articles for article (PubMed ID: 35151105)
1. Refining M1 stage in medulloblastoma: criteria for cerebrospinal fluid cytology and implications for improved risk stratification from the HIT-2000 trial.
Hagel C; Sloman V; Mynarek M; Petrasch K; Obrecht D; Kühl J; Deinlein F; Schmid R; von Bueren AO; Friedrich C; Juhnke BO; Gerber NU; Kwiecien R; Girschick H; Höller A; Zapf A; von Hoff K; Rutkowski S
Eur J Cancer; 2022 Mar; 164():30-38. PubMed ID: 35151105
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of cerebrospinal fluid cytology in pediatric medulloblastoma. Swiss Pediatric Oncology Group.
Miralbell R; Bieri S; Huguenin P; Feldges A; Morin AM; Garcia E; Wagner HP; Wacker P; von der Weid N
Ann Oncol; 1999 Feb; 10(2):239-41. PubMed ID: 10093696
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of intracranial cerebrospinal fluid cytology in staging pediatric medulloblastomas, supratentorial primitive neuroectodermal tumors, and ependymomas.
Terterov S; Krieger MD; Bowen I; McComb JG
J Neurosurg Pediatr; 2010 Aug; 6(2):131-6. PubMed ID: 20672933
[TBL] [Abstract][Full Text] [Related]
4. Clinical and molecular characterization of isolated M1 disease in pediatric medulloblastoma: experience from the German HIT-MED studies.
Obrecht D; Mynarek M; Hagel C; Kwiecien R; Spohn M; Bockmayr M; Bison B; Pfister SM; Jones DTW; Sturm D; von Deimling A; Sahm F; von Hoff K; Juhnke BO; Benesch M; Gerber NU; Friedrich C; von Bueren AO; Kortmann RD; Schwarz R; Pietsch T; Fleischhack G; Schüller U; Rutkowski S
J Neurooncol; 2022 Mar; 157(1):37-48. PubMed ID: 35190934
[TBL] [Abstract][Full Text] [Related]
5. Nonmetastatic Medulloblastoma of Early Childhood: Results From the Prospective Clinical Trial HIT-2000 and An Extended Validation Cohort.
Mynarek M; von Hoff K; Pietsch T; Ottensmeier H; Warmuth-Metz M; Bison B; Pfister S; Korshunov A; Sharma T; Jaeger N; Ryzhova M; Zheludkova O; Golanov A; Rushing EJ; Hasselblatt M; Koch A; Schüller U; von Deimling A; Sahm F; Sill M; Riemenschneider MJ; Dohmen H; Monoranu CM; Sommer C; Staszewski O; Mawrin C; Schittenhelm J; Brück W; Filipski K; Hartmann C; Meinhardt M; Pietschmann K; Haberler C; Slavc I; Gerber NU; Grotzer M; Benesch M; Schlegel PG; Deinlein F; von Bueren AO; Friedrich C; Juhnke BO; Obrecht D; Fleischhack G; Kwiecien R; Faldum A; Kortmann RD; Kool M; Rutkowski S
J Clin Oncol; 2020 Jun; 38(18):2028-2040. PubMed ID: 32330099
[TBL] [Abstract][Full Text] [Related]
6. Prognostic effect of whole chromosomal aberration signatures in standard-risk, non-WNT/non-SHH medulloblastoma: a retrospective, molecular analysis of the HIT-SIOP PNET 4 trial.
Goschzik T; Schwalbe EC; Hicks D; Smith A; Zur Muehlen A; Figarella-Branger D; Doz F; Rutkowski S; Lannering B; Pietsch T; Clifford SC
Lancet Oncol; 2018 Dec; 19(12):1602-1616. PubMed ID: 30392813
[TBL] [Abstract][Full Text] [Related]
7. Treatment results of adults and children with medulloblastoma NCI, Cairo University experience.
Khalil EM
J Egypt Natl Canc Inst; 2008 Jun; 20(2):175-86. PubMed ID: 20029474
[TBL] [Abstract][Full Text] [Related]
8. Postoperative neoadjuvant chemotherapy before radiotherapy as compared to immediate radiotherapy followed by maintenance chemotherapy in the treatment of medulloblastoma in childhood: results of the German prospective randomized trial HIT '91.
Kortmann RD; Kühl J; Timmermann B; Mittler U; Urban C; Budach V; Richter E; Willich N; Flentje M; Berthold F; Slavc I; Wolff J; Meisner C; Wiestler O; Sörensen N; Warmuth-Metz M; Bamberg M
Int J Radiat Oncol Biol Phys; 2000 Jan; 46(2):269-79. PubMed ID: 10661332
[TBL] [Abstract][Full Text] [Related]
9. Identification of low and very high-risk patients with non-WNT/non-SHH medulloblastoma by improved clinico-molecular stratification of the HIT2000 and I-HIT-MED cohorts.
Mynarek M; Obrecht D; Sill M; Sturm D; Kloth-Stachnau K; Selt F; Ecker J; von Hoff K; Juhnke BO; Goschzik T; Pietsch T; Bockmayr M; Kool M; von Deimling A; Witt O; Schüller U; Benesch M; Gerber NU; Sahm F; Jones DTW; Korshunov A; Pfister SM; Rutkowski S; Milde T
Acta Neuropathol; 2023 Jan; 145(1):97-112. PubMed ID: 36459208
[TBL] [Abstract][Full Text] [Related]
10. M1 Medulloblastoma: high risk at any age.
Sanders RP; Onar A; Boyett JM; Broniscer A; Morris EB; Qaddoumi I; Armstrong GT; Boop FA; Sanford RA; Kun LE; Merchant TE; Gajjar A
J Neurooncol; 2008 Dec; 90(3):351-5. PubMed ID: 18704266
[TBL] [Abstract][Full Text] [Related]
11. Cerebrospinal fluid M staging for medulloblastoma: reappraisal of Chang's M staging based on the CSF flow.
Phi JH; Lee J; Wang KC; Cho BK; Kim IO; Park CK; Kim CY; Ahn HS; Kim IH; Kim SK
Neuro Oncol; 2011 Mar; 13(3):334-44. PubMed ID: 21134897
[TBL] [Abstract][Full Text] [Related]
12. Long-term outcomes and role of chemotherapy in adults with newly diagnosed medulloblastoma.
Call JA; Naik M; Rodriguez FJ; Giannini C; Wu W; Buckner JC; Parney IF; Laack NN
Am J Clin Oncol; 2014 Feb; 37(1):1-7. PubMed ID: 23111362
[TBL] [Abstract][Full Text] [Related]
13. A long duration of the prediagnostic symptomatic interval is not associated with an unfavourable prognosis in childhood medulloblastoma.
Gerber NU; von Hoff K; von Bueren AO; Treulieb W; Deinlein F; Benesch M; Zwiener I; Soerensen N; Warmuth-Metz M; Pietsch T; Mittler U; Kuehl J; Kortmann RD; Grotzer MA; Rutkowski S
Eur J Cancer; 2012 Sep; 48(13):2028-36. PubMed ID: 22153558
[TBL] [Abstract][Full Text] [Related]
14. Metastasis stage, adjuvant treatment, and residual tumor are prognostic factors for medulloblastoma in children: conclusions from the Children's Cancer Group 921 randomized phase III study.
Zeltzer PM; Boyett JM; Finlay JL; Albright AL; Rorke LB; Milstein JM; Allen JC; Stevens KR; Stanley P; Li H; Wisoff JH; Geyer JR; McGuire-Cullen P; Stehbens JA; Shurin SB; Packer RJ
J Clin Oncol; 1999 Mar; 17(3):832-45. PubMed ID: 10071274
[TBL] [Abstract][Full Text] [Related]
15. Is there a correlation between duration of presenting symptoms and stage of medulloblastoma at the time of diagnosis?
Halperin EC; Friedman HS
Cancer; 1996 Aug; 78(4):874-80. PubMed ID: 8756384
[TBL] [Abstract][Full Text] [Related]
16. Treatment of high-risk medulloblastoma and other primitive neuroectodermal tumors with reduced dose craniospinal radiation therapy and multi-agent nitrosourea-based chemotherapy.
Prados MD; Wara W; Edwards MS; Ater J; Rabbit J; Lamborn K; Davis R; Levin VA
Pediatr Neurosurg; 1996 Oct; 25(4):174-81. PubMed ID: 9293544
[TBL] [Abstract][Full Text] [Related]
17. Comparison of CSF cytology and spinal magnetic resonance imaging in the detection of leptomeningeal disease in pediatric medulloblastoma or primitive neuroectodermal tumor.
Fouladi M; Gajjar A; Boyett JM; Walter AW; Thompson SJ; Merchant TE; Jenkins JJ; Langston JW; Liu A; Kun LE; Heideman RL
J Clin Oncol; 1999 Oct; 17(10):3234-7. PubMed ID: 10506624
[TBL] [Abstract][Full Text] [Related]
18. Myelography for staging medulloblastoma.
Deutsch M; Laurent JP; Cohen ME
Cancer; 1985 Oct; 56(7 Suppl):1763-6. PubMed ID: 4027907
[TBL] [Abstract][Full Text] [Related]
19. Fluorescence Lifetime Imaging Microscopy, a Novel Diagnostic Tool for Metastatic Cell Detection in the Cerebrospinal Fluid of Children with Medulloblastoma.
Gershanov S; Michowiz S; Toledano H; Yahav G; Barinfeld O; Hirshberg A; Ben-Zvi H; Mircus G; Salmon-Divon M; Fixler D; Goldenberg-Cohen N
Sci Rep; 2017 Jun; 7(1):3648. PubMed ID: 28623325
[TBL] [Abstract][Full Text] [Related]
20. Correlation of MRI and CSF cytology in the diagnosis of medulloblastoma spinal metastases.
Harrison SK; Ditchfield MR; Waters K
Pediatr Radiol; 1998 Aug; 28(8):571-4. PubMed ID: 9716623
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
